Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21985823 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3AMDHD2ALDH1A1THRB | |
| SCHEMBL16640643 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3AMDHD2ALDH1A1THRB | |
| SCHEMBL16644661 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3AMDHD2ALDH1A1THRB | |
| SCHEMBL16640655 | 0.91 | MAPK1 (0.51) | MAPK1LGALS3AMDHD2ALDH1A1THRB | |
| SCHEMBL22204677 | 0.90 | MAPK1 (0.44) | MAPK1LGALS3ALDH1A1THRBTLR4 | |
| SCHEMBL31076331 | 0.89 | MAPK1 (0.62) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL31076211 | 0.89 | MAPK1 (0.62) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL25043094 | 0.83 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL13491439 | 0.83 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL13308281 | 0.83 | MAPK1 (0.56) | MAPK1LGALS3ALDH1A1THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668143-B2 | Meningococcus serogroup X conjugate | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2020-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668143-B2 | Meningococcus serogroup X conjugate | O60361, MLEC, PDHX | MAPK1 3561/4885LGALS3 1740/4885AMDHD2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.